Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Central Neuropathic Pain: early-phase trial registry

2 of 3 indexed Central Neuropathic Pain trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Central Neuropathic Pain: 3 US clinical trials tracked, 2 recruiting.

Central Neuropathic Pain is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Brigham and Women's Hospital, running 1 of these trials.

Enrollment posture brief

Registry condition central-neuropathic-pain

OPEN 2 | RECR 67% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1

Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Central Neuropathic Pain (th…67%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Central Neuropathic Pain

Central Neuropathic Pain lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Central Neuropathic Pain on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Central Neuropathic Pain is recruiting above its size-band peers.

    2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 23

Phase Distribution

PhaseTrial count
Phase 2 3

Named interventions

Most-linked intervention names on Central Neuropathic Pain records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo (Lidocaine) Drug
1 trials
Placebo (Dextromethorphan) Drug
1 trials
Dextromethorphan Drug
1 trials
4.5mg daily dose of naltrexone Drug
1 trials
Nitrous oxide gas for inhalation Drug
1 trials
Lidocaine Drug
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Central Neuropathic Pain trials. A trial with sites in several states counts in each.

Wisconsin 1 trials
Massachusetts 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Central Neuropathic Pain page

3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Central Neuropathic Pain condition card totals 3 registered trials; most-linked intervention Placebo (Lidocaine); top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.